Immunicum AB (1YG0) Price & Analysis

1 Followers

1YG0 Stock Chart & Stats

€0.49

-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.49

-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.35 - €0.84

Previous CloseN/A

Volume0.00

Average Volume (3M)16.00

Market Cap

€40.07M

Enterprise Value€220.43

Total Cash (Recent Filing)€74.13M

Total Debt (Recent Filing)€18.67M

Price to Earnings (P/E)―

Beta0.25

Next Earnings

Aug 20, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.90

Shares Outstanding64,784,580

10 Day Avg. Volume50

30 Day Avg. Volume16

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)0.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.14

Revenue Forecast (FY)€452.03K

Bulls Say, Bears Say

Bulls Say

Clinical-stage Immuno-oncology PlatformImmunicum’s core is a clinical-stage cell‑based immuno‑oncology platform. That durable scientific focus creates high-value optionality: successful clinical outcomes can drive licensing, partnerships, or product commercialization, and the platform aligns with long-term oncology demand trends.

Low Financial LeverageThe company’s low debt burden reduces solvency and interest-rate pressure, preserving financial flexibility. For a R&D‑heavy biotech, modest leverage lowers bankruptcy risk and supports the ability to fund trials or negotiate partnerships without large fixed financing costs over the medium term.

Lean OrganizationA compact team can limit fixed costs and help extend cash runway relative to larger peers. Combined with reported smaller cash burn in 2024–2026 versus 2023, a lean structure improves near‑term sustainability and preserves optionality for strategic collaborations or staged financing.

Bears Say

Zero Recent RevenueThe absence of product revenue means the company lacks recurring commercial cash flows, leaving its operating model dependent on achieving clinical milestones. This structural gap increases funding dependency and delays any path to self‑sustaining operations until commercialization or licensing occurs.

Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates the business is not self‑funding. Even with some burn improvement, ongoing losses necessitate external capital, compress management choices, and increase dilution or restructuring risk if financing terms tighten over the medium term.

Reliance On External FinancingAs a clinical‑stage biotech without marketed products, Immunicum depends on equity raises, partnerships, or grants to fund R&D. This structural financing reliance raises dilution risk, creates timing uncertainty for programs, and ties progress to capital market conditions or partner interest.

1YG0 FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was €0.35 and its highest was €0.84 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is €40.07M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is Aug 20, 2026 which is in 17 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on May 08, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.031.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate is -0.04.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 64,784,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -€0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.226%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in DE:1YG0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.